Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2017-04-28 Report Publication Anno…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 99% confidence The document is titled "Mise à disposition du Document de Référence 2016" (Making available of the 2016 Reference Document). It explicitly states that the 'document de référence 2016 contenant le Rapport Financier Annuel' (2016 reference document containing the Annual Financial Report) has been registered with the AMF. Crucially, the document itself is very short (3524 characters) and its primary function is to announce that the main report is available on the company's website and the AMF website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is attached classifies the filing as a Report Publication Announcement (RPA), rather than the full report itself (which would likely be a 10-K or IR if comprehensive).
2017-04-28 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release from NANOBIOTIX announcing the successful completion of a private placement of new ordinary shares, raising approximately 25.1 million Euros. Key phrases include "NANOBIOTIX LEVE 25,1 MILLIONS D'EUROS DANS LE CADRE D'UN PLACEMENT PRIVE D'ACTIONS ORDINAIRES NOUVELLES" and details about the issuance of new shares, the issue price, and the use of proceeds. This activity directly relates to fundraising, financing activities, and changes in the capital structure. Based on the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it describes a specific corporate finance transaction.
2017-04-07 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is an announcement titled "NANOBIOTIX SUCCESSFULLY COMPLETES APPROX. EUR 25.1 MILLION PRIVATE PLACEMENT OF NEW SHARES". It details the successful completion of a private placement (fundraising activity) involving the issuance of new shares to qualified institutional investors. This directly relates to the company's capital structure and fundraising efforts. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a formal Annual Report (10-K). The document is a press release announcing a specific financial transaction.
2017-04-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is a press release from NANOBIOTIX announcing a plan to issue new shares through an accelerated book-building process ('construction accélérée d'un livre d'ordre') to raise capital. Key phrases include 'AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D'UN LIVRE D'ORDRE' and details about the intended use of proceeds and the involvement of bookrunners. This activity directly relates to fundraising, financing activities, and changes in capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2017-04-06 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is titled "NANOBIOTIX LAUNCHES CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING" and details the intent to issue new shares through an offering. This activity directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves share issuance, the primary focus is the financing event (the offering) rather than just the resulting share change (SHA) or a buyback (POS). The document is a press release announcing the financing terms, not a regulatory filing like a 10-K or a short announcement of a report (RPA/RNS).
2017-04-06 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of March 31, 2017. This structure is characteristic of a mandatory regulatory disclosure in France concerning the total share capital and voting rights, which is typically filed monthly. This specific disclosure type is not explicitly listed in the provided definitions, but it relates to capital structure changes and shareholder information. Given the options, it is a specific regulatory filing that doesn't fit 10-K, ER, or IR. It is most closely related to capital structure updates or general regulatory announcements. Since it reports on the total number of shares and voting rights, it is a specific type of capital/share information disclosure. However, none of the codes perfectly match a 'Monthly Voting Rights Disclosure'. The closest related codes are 'SHA' (Share Issue/Capital Change) or 'RNS' (Regulatory Filings - fallback). Since this is a routine, mandatory disclosure about the current state of the capital structure (not an announcement of a change like a new issue or buyback, but a snapshot), and it is a specific regulatory filing, 'RNS' (Regulatory Filings) serves as the best general fit for a mandatory, non-standard report type, although 'SHA' touches upon the subject matter (shares/capital). Given the highly specific nature of the content (voting rights count), and lacking a specific code for this, 'RNS' is the most appropriate fallback for a mandatory regulatory disclosure that doesn't fit the other specific categories like ER, IR, or 10-K. The document is short and is the report itself, not an announcement of a report.
2017-04-05 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.